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TRENDS IN METHICILLIN-RESISTANT STAPHYLOCOCCUS
AUREUS (MRSA) BLOODSTREAM INFECTIONS: EFFECT OF
THE MRSA “SEARCH AND ISOLATE” STRATEGY IN A
HOSPITAL IN ITALY WITH HYPERENDEMIC MRSA
Angelo Pan, MD; Giuseppe Carnevale, MD; Patrizia Catenazzi; Paolo Colombini, MD; Luciano Crema, MD; Lucia Dolcetti, MD;
Lucio Ferrari, PhD; Placido Mondello, MD; Liana Signorini, MD; Carmine Tinelli, MD; Eugenia Quiros Roldan, MD;
Giampiero Carosi, MD
Staphylococcus aureus is the most common human
pathogen,1 and infections caused by methicillin-resistant
S. aureus (MRSA) are increasing in most hospitals
throughout the world.2 MRSA is one of the most common
nosocomial pathogens in Europe3,4 and North America.5
Recent data have revealed that hospitals in Italy have
some of the highest MRSA incidence rates in Europe,
ranging from 30% to 40%.6,7
The incidence rates of S. aureus bloodstream infec-
tion (BSI) have increased over the years,8 and MRSA BSIs
are associated with increased mortality compared with
methicillin-sensitive (MSSA) BSIs.9,10
MRSA infections also are frequent in high-risk pop-
ulations, such as patients in intensive care units (ICUs),5
patients with central venous catheters (CVCs),11 or liver
transplant recipients.12 Patients colonized with MRSA are
at higher risk for MRSA BSIs than are patients colonized
with MSSA.13
Nosocomial infection control programs have been
implemented in many countries,14 and several of these
programs are based on the “search and isolate” strategy
to control the nosocomial spread of MRSA. There are
fewer data on the efficacy of these control interventions
for MRSA BSIs, particularly where the prevalence of
MRSA exceeds 50%. 
We evaluated the incidence rate of MRSA BSIs by
ward and possible origin, before and after the introduc-
tion of a control program at the hospital of Cremona, Italy.
The prevalence of methicillin resistance among nosoco-
mial isolates of S. aureus at the time of the intervention
was greater than 50% in this hospital.
METHODS
Study Design and Period
This was an interventional before–after study. Data
regarding MRSA or MSSA BSIs were collected from
January 1, 1996, through December 31, 2001. From
January 1, 1997, through December 31, 2001, identifica-
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OBJECTIVE: To evaluate the secular trends in MRSA
BSIs after the introduction of a nosocomial MRSA control inter-
vention.
DESIGN: Before–after study. 
SETTING: An 850-bed community hospital with an ICU
and vascular surgery, neurosurgery, bone marrow transplanta-
tion, and AIDS units. MRSA is endemic at this hospital; the preva-
lence of methicillin resistance among patients with S. aureus
infection is greater than 50%.
PATIENTS: Among all inpatients, MRSA BSI was identi-
fied, its origin defined, and incidence rates calculated by ward
and origin. 
INTERVENTION: A MRSA control program was imple-
mented based on active surveillance cultures to identify MRSA-
colonized patients, followed by isolation using contact precau-
tions. Incidence rates of MRSA BSI during the intervention (ie,
July 1, 1997, to December 31, 2001) and preintervention (ie,
January 1, 1996, to June 30, 1997) periods were compared.
RESULTS: Sixty-nine MRSA BSIs were identified. When
compared with the preintervention period, the incidence rate of
MRSA BSI was reduced from 0.64 to 0.30 per 1,000 admissions
(RR, 0.46; CI95, 0.25–0.87; P = .02) during the intervention period.
The impact was greater in the ICU, with an 89% reduction (RR,
0.11; CI95, 0.01–0.98; P = .03), and for CVC-associated MRSA
BSIs, with an 82% decrease (RR, 0.17; CI95, 0.05–0.55; P = .002).
Methicillin resistance among S. aureus blood isolates decreased
from 46% to 17% (RR, 0.36; CI95, 0.22–0.62; P = .0002).
CONCLUSION: A reduction in MRSA bacteremia is
achievable through use of the MRSA “search and isolate” inter-
vention even in a hospital with high rates of endemic MRSA
(Infect Control Hosp Epidemiol 2005;26:127-133).
ABSTRACT
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tion was prospective, whereas during 1996, identification
was retrospective.
For the purpose of analysis, three periods were iden-
tified. The preintervention period (from January 1, 1996,
through June 30, 1997) was the period before the intro-
duction of the program to control nosocomial transmission
of MRSA (Period “Pre”). Intervention period A (from July
1, 1997, through December 31, 1999) was the first part of
the intervention period, when the program was progres-
sively introduced on each ward and service. An education-
al program for healthcare workers regarding the new
infection control measures was implemented. Intervention
period B (from January 1, 2000, to December 31, 2001)
was the final part of the study period, when the search and
destroy protocols were fully implemented.
Setting
The study was conducted at the hospital of
Cremona in Lombardy, Italy. The hospital is an 850-bed
community hospital with medical and surgical wards, one
general ICU, a neonatal ICU, a vascular surgery unit, a
bone marrow transplantation unit, and an infectious dis-
eases and acquired immunodeficiency syndrome (AIDS)
unit. A neurosurgery unit was opened in 1999. The hospi-
tal of Cremona admits approximately 25,000 patients each
year.
When the intervention was initiated in the hospital of
Cremona, like most Italian hospitals, it was characterized by
(1) isolation of MRSA in the hospital for more than 10 years,
(2) a high rate of transmission of MRSA (ie, more than 5
cases per 1,000 admissions15), and (3) a high rate of methi-
cillin resistance among nosocomial isolates of S. aureus
(> 50%).
Intervention 
In July 1997, on the basis of the available litera-
ture,16-20 we introduced a program to control nosocomial
MRSA transmission within the hospital of Cremona
using a multicomponent approach similar to the search
and isolate system.21 The key points of the program
were: 
1. Active Surveillance Cultures for MRSA:
Obtaining Nasal Swabs From High-Risk
Patients and Wards. An initial exploratory study was
performed before the intervention to identify patients and
wards at higher risk of MRSA colonization (unpublished
data). High-risk patients were identified as those trans-
ferred from the intensive care, heart surgery, or neuro-
surgery units of other hospitals and nursing homes resi-
dents. High-risk wards were identified as ICUs, post-ICU
rehabilitation units, and bone marrow transplantation
units. 
Nasal swabs were obtained on admission for these
high-risk patients and wards. On high-risk wards, nasal
swabs were performed periodically to identify MRSA-col-
onized patients. They were performed at different times
on different wards, depending on the intensity of care:
every 3 days in the ICU, every week in the bone marrow
transplantation unit, and every 2 weeks in the rehabilita-
tion unit. The different time points were based on the
median time to MRSA positivity identified in these wards
through a pilot study (unpublished data).
2. Isolation and Contact Precautions for
All Identified MRSA-Positive (Colonized or
Infected) Patients. Contact precautions included rou-
tine glove use and handwashing; gowns were used only
when treating patients with infected wounds. The contact
precautions protocol was simplified to save healthcare
workers’ time and possibly improve their compliance.
3. Treatment of MRSA-Positive Patients
With Nasal Mupirocin Ointment. Mupirocin oint-
ment (Bactroban pomata, GlaxoSmithKline, Verona,
Italy), 2 to 3 mm in each nostril 3 times daily; chlorhexi-
dine 4% soap solution (Neoxidina mani, Farmec, Settimo
di Pescantino - VR, Italy) baths or showers, once a day for
5 days; and shampoos on the first and fifth day of treat-
ment were administered to MRSA-positive patients.
Colonized wounds were treated with polyethylenglycol
mupirocin cream (Bactroban crema, GlaxoSmithKline)
twice a day for 5 days.
4. Periodic Feedback of MRSA Data to
Medical and Non-Medical Ward Staff. Data from
MRSA-positive patients were entered into a database.
Other than MRSA control, no specific intervention
to reduce BSIs caused by other pathogens was imple-
mented during the study period.
Patients
The study included all inpatients from January 1,
1996, through December 31, 2001, who had at least one
blood culture positive for MRSA or MSSA. 
Microbiology
All blood cultures were processed by the hospital’s
microbiology laboratory using the Bactec 9240 System
(Becton Dickinson, Milan, Italy). Staphylococcus species
were identified using the API System (API Staph,
bioMérieux, Rome, Italy). Antimicrobial susceptibility
testing was performed using the Sceptor System (Becton
Dickinson) with a 3-point breakpoint according to
National Committee for Clinical Laboratory Standards
guidelines.22 Methicillin resistance was confirmed
through growth identification using the Oxa Screen Agar
System (Becton Dickinson). 
Overall Hospital Population Data
The number of admissions per ward per month and
the number of surgical procedures were obtained from the
hospital’s computer system. Data regarding the number of
CVCs were obtained from the registers of the wards where
the CVCs were inserted, specifically the ICU, general sur-
gical wards, and nephrology and dialysis wards.
Clinical Chart Analysis 
An active surveillance system was established with
the clinical microbiology laboratory. Three to five times a
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week, a member of the infection control team visited the
laboratory and entered any S. aureus isolated from blood
cultures into the database.
Patients’ medical records were reviewed after
patient discharge, and the origin of MRSA BSI was
defined. All data were entered in the database. 
Definitions: Origin of MRSA Bacteremia 
The definition of MRSA BSI was based on the
Centers for Disease Control and Prevention definitions of
nosocomial infection23 or the 1996 guidelines on CVC-
related MRSA BSI,24 as appropriate. A final review of each
CVC-associated MRSA BSI was performed using the def-
initions of CVC-related bacteremia as indicated by the
2001 guidelines.25 The differences between the 1996 and
the 2001 guidelines are minimal: (1) the introduction of
paired blood cultures with differential time to positivity
and (2) the reduction of the colony-forming units from
103 to 102, obtained through quantitative culture of a seg-
ment of the catheter, for a catheter to be considered
infected. The use of paired blood cultures was introduced
in our hospital in June 2000. At the same time, the use of
quantitative blood cultures was discontinued. Because
CVC-associated MRSA BSIs were considered as a sepa-
rate group, a BSI was considered as primary if 
no source, not even an intravascular catheter, was identi-
fied. 
MRSA BSI was defined as secondary to surgical-site
infection (SSI) when MRSA was isolated from a swab of
the surgical site or in the absence of a microbiological
sample obtained from the surgical site.
Isolates were identified as either nosocomial or
community acquired. Isolates were defined as community
acquired when cultures were performed less than 48
hours after admission. An isolate was defined as nosoco-
mial if the culture was performed more than 48 hours
after admission. 
A patient was defined as MRSA positive when the
pathogen was isolated from at least one site on at least one
occasion. MRSA-positive patients could be either infected
or colonized.
A wound was defined as colonized if no sign of local
infection was present and MRSA was isolated from a
wound swab.
Statistical Analysis
Results were expressed as incidence rate and rela-
tive risk (RR) with 95% confidence interval (CI95).
Statistical analyses were performed using the statistical
process control method and quality control charts.26
Control charts compare a current performance with a
past performance to indicate whether they are in statisti-
cal control. The analysis uses the mean score and ± 3 stan-
dard deviations (SDs) to determine whether a change in
the data is due to chance. With the use of the 2-band
analysis it is assumed that if data are outside the bands, it
is a statistically significant change or event at the .05 level.
Dif ferences in frequencies were evaluated by
means of chi-square or Fisher’s exact test, as appro-
priate.
A P value less than .05 was considered to indicate
statistical significance; all tests were two-sided. Analyses
were performed using STATA software (release 7.0;
STATA Corp., College Station, TX).
RESULTS 
During the 6-year study period, there were 156,871
admissions and 47,032 surgical procedures (surgical pro-
cedures increased progressively from approximately
6,000 in 1996 to approximately 9,000 in 2001). The number
of CVCs inserted increased significantly during the study
period from 13.9 per 1,000 admissions in the preinterven-
tion period to 16.9 in intervention period A and 26.6 in
intervention period B. 
During the study period, 251 episodes of S. aureus
BSI were identified (1.6 cases per 1,000 admissions); 69
(27.5%) were due to MRSA (0.44 per 1,000 admissions).
MRSA BSI developed in 7.8% of the 885 MRSA-positive
patients. All MRSA BSIs identified were healthcare relat-
ed; no community MRSA BSIs were identified.
The rate of methicillin resistance among blood iso-
lates of S. aureus was 46% in the first 18 months (prein-
tervention) and decreased to 17% in intervention period B
(P = .0001). During intervention periods A and B, the pro-
portion of S. aureus isolates with methicillin resistance
was 21%; this was a significant reduction compared with
the preintervention period (P = .0003).
The incidence rate of MRSA BSI decreased by 42%,
from 0.64 case per 1,000 admissions in the preinterven-
tion period to 0.37 case per 1,000 admissions during the
entire intervention period (RR, 0.57; CI95, 0.35 to 0.92; P =
.03). The secular trend had a bimodal form, with an initial
decline in MRSA BSI during the first 2 years of the inter-
vention (approximately 31%) and a smaller secondary
decline (24%) in the last 2 years of the intervention. When
the preintervention period and intervention period B
were compared, the decrease in MRSA BSIs (to 0.46 case
per 1,000 admissions) was statistically significant (P = .02)
(Figure).
Next, we evaluated the impact by ward. Of the
MRSA BSIs, 40 (58%) of 69 were identified in medical
wards, 20 (29%) in surgical wards, and 9 (13%) in the ICU.
A significant decrease in the incidence rate of MRSA
BSIs was obtained in all wards and units. The greatest
impact was in the ICU, where there was a 56% reduction
(RR, 0.44) between the preintervention period and inter-
vention period A (from 6.07 to 2.66 cases per 1,000 admis-
sions) and an 89% reduction between the preintervention
period and intervention period B, when the MRSA BSI
incidence rate decreased to 0.66 case per 1,000 admissions
(RR, 0.11).
On the medical wards, the MRSA BSI rate
decreased from 0.59 case per 1,000 admissions in the
preintervention period to 0.43 case per 1,000 admissions
in intervention period A (RR, 0.73) and subsequently to
0.36 MRSA BSI per 1,000 admissions (RR, 0.61) in inter-
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vention period C (Table 1). In the surgical wards, the
reduction observed between the preintervention and the
entire postintervention period (ie, periods A and B) was
approximately 50% (RR, 0.48; CI95, 0.2 to 1.16; P = .15). The
MRSA BSI incidence rate was 0.51 case per 1,000 admis-
sions in the preintervention period and 0.21 in interven-
tion period B (RR, 0.41) (Table 1).
Next, we evaluated the origin of MRSA BSI.
Twenty-nine MRSA BSIs (42%) were CVC associated, 20
(29%) were secondary to SSI, and 10 (14%) were primary.
Five MRSA BSIs (7%) originated from skin disease (name-
ly, pressure sores, wounds, or abscesses), 3 (5%) originat-
ed from respiratory tract infections, and 2 (3%) were sec-
ondary to urinary tract infection.
Next, we evaluated the incidence rate of CVC-asso-
ciated MRSA BSIs in patients who had a CVC inserted. A
31% decrease in MRSA BSI was detected from the prein-
tervention period to intervention period B (1.71 to 1.18
MRSA BSIs per 100 CVCs). During intervention period B,
there was an 82% reduction in CVC-associated MRSA
BSIs, with the incidence rate decreasing to 0.3 case per
100 CVCs (RR, 0.17) (Table 2). No difference was identi-
fied in the diagnosis of CVC-associated MRSA BSIs using
the 1996 or the 2001 definitions.
The incidence rate of primary MRSA BSI decreased
71% between the preintervention and the entire postinter-
vention periods, from 0.12 to 0.03 case per 1,000 admis-
sions (RR, 0.29; CI95, 0.08 to 1.09; P = .06).
MRSA BSIs due to SSI were reduced by 49%, from
0.73 during the preintervention period to 0.37 per 1,000
surgical procedures during the entire intervention period
(ie, periods A and B) (RR = 0.51; CI95, 0.21 to 1.27; P = .17).
The incidence rate of MSSA BSI rose from 0.81 case
per 1,000 admissions in the preintervention period to 1.1
cases in intervention period A (RR, 1.37; CI95, 0.91 to 2.05;
P = .16). There was a further increase to 1.59 cases per
1,000 admissions (RR, 1.96; CI95, 1.32 to 2.93; P = .001) in
intervention period B.
The percentage of all nosocomial S. aureus isolates
with methicillin resistance progressively decreased from
53% in the preintervention period to 21% in intervention
period B (P < .0001).
Finally, data regarding compliance with contact pre-
cautions were available for 370 of 741 patients positive for
MRSA after the introduction of the control program.
Contact precautions were correctly applied for 203 (55%)
of 370 patients. In another 25 MRSA-positive patients (7%),
the culture results were not available until the day of or
after hospital discharge. Thus, the overall compliance rate
for patients known to be MRSA positive during hospital-
ization was 62%.
DISCUSSION
The introduction of a search and isolate strategy to
control nosocomial transmission of MRSA in a hospital with
high endemic levels of MRSA led to a significant reduction
in MRSA BSI. The control program was most effective in
reducing MRSA BSIs among patients with CVCs and those
in the ICU. The implications of these results are interesting
for different reasons. A significant reduction in MRSA BSIs
is feasible even in settings with high MRSA rates. Although
partial control of MRSA in settings with high levels of
MRSA has been previously achieved,27-29 there are few, if
any, reports of a reduction in MRSA BSIs in hospitals with
MRSA rates greater than 40%. Although complete eradica-
tion of MRSA BSIs from the hospital was not achieved, the
results obtained were significant and impressive. 
S. aureus BSIs arise from the patients’ own flora in
approximately 80% of episodes.30,31 There may be several
explanations for our failure to fully eradicate MRSA BSIs,
including failure to detect all MRSA-positive patients
(unknown carriers pose a much higher risk of transmit-
ting MRSA than known carriers32); incomplete adherence
to the isolation protocol, particularly to hand hygiene pro-
cedures (adherence to the protocol in our hospital was
62%); oversimplification of the isolation protocol
(although gowns are an effective adjunctive means to con-
trol nosocomial transmission of MRSA,33 we recommend-
ed them only for patients with purulent infections); delay
in adherence to the MRSA protocol after patient admis-
sion; and changes in the patient population at the hospital,
with an increase in the population at risk during the study
period. Between 1996 and 2001, there was a significant
increase in CVC insertions, a known risk factor for MRSA
BSIs.13,34 Probably more than one of these factors played
a role in the incomplete success of the program. 
As per the origin, the most striking reduction was
seen among CVC-associated MRSA BSIs. CVC-associated
MRSA BSIs decreased by 82%. Because no other program
for prevention of CVC-associated infection was imple-
mented during the study period, which could have modi-
fied the incidence rate of CVC-associated BSIs (and MSSA
FIGURE. Quality control chart26 demonstrating the incidence of methicillin-
resistant Staphylococcus aureus (MRSA) bacteremia per 1,000 admissions
during the 3 phases of the study period. The solid line indicates the month-
ly incidence of MRSA bacteremia. The dotted line indicates the upper band
of alarm of MRSA bacteremia, calculated with the mean incidence plus 3
standard deviations. The lower band of alarm, calculated with the mean
incidence minus 3 standard deviations, corresponds to 0 during the entire
period. With the use of the 2-band analysis it is assumed that if data are
outside the bands, it is a statistically significant change or event at the .05
level. Period A corresponds to the preintervention phase. Period B repre-
sents the first period after the introduction of the control program, and
period C the last 2 years of the study period, when the program was well
known throughout the hospital.
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BSIs did increase), the reduction we observed was proba-
bly due to the MRSA intervention program itself.
Although a reduction in the number of MRSA-colo-
nized patients could explain the reduction in CVC-associ-
ated MRSA BSIs, there is an alternative hypothesis: the
decrease in the prevalence of MRSA-colonized patients,
due to topical treatment with mupirocin and chlorhexi-
dine, could reduce the risk of MRSA BSI. This hypothesis
may be indirectly supported by the findings that SSIs are
more frequently seen in heavily colonized patients (ie,
nose and rectum) as compared with patients with only
nasal colonization.35 Topical treatment is only partially
effective in eliminating MRSA carriage,36 whereas it is
probably very effective in reducing the overall body bac-
terial count, possibly reducing the risk of CVC-associated
MRSA BSIs.
The reduction was most consistent in patients
admitted to the ICU, where the incidence rate of MRSA
BSIs decreased by 89%. CVCs were the most frequent site
of origin of MRSA BSIs in the ICU both before (3 of 4;
75%) and after (5 of 5; 100%) the introduction of the inter-
vention program. Although this could be due, at least part-
ly, to the reduction in CVC-associated MRSA BSIs, we
think that the reduction in the reservoir of MRSA-colo-
nized patients, secondary to reduced cross-transmission
rates of MRSA, had a central role in this result. The ICU
was where our intervention was the most aggressive in
searching for MRSA-colonized patients. Aggressive
search and destroy systems are known to be successful in
controlling nosocomial MRSA transmission in hospitals,37
and effective programs are generally characterized by the
presence of an active surveillance culture program aimed
at identifying MRSA carriers.33
Approximately 24 months after the introduction of
the program, a baseline level of MRSA BSI was reached
(ie, 0.3 case per 1,000 admissions) and remained stable
for the following 2 years. The reasons for this bimodal pat-
tern may be that (1) such a control program shows a high
efficiency in a hyperendemic setting, whereas in settings
with lower incidences of transmission and infection a
more aggressive approach is probably needed; and (2) the
incomplete adherence to the isolation protocol (62%) did
not permit a further reduction of the transmission of
MRSA. It is possible that different levels of transmission
need different approaches, such as the very aggressive
“Dutch system”37 or a dedicated infection control nurse in
high-risk units.38
Finally, a significant reduction in methicillin resis-
tance among blood isolates was seen: 46% during the first 18
months as compared with 17% in the last 2 years of the study
period (P = .0001). In the ICU, the rate of methicillin resis-
tance among blood isolates was similarly reduced from 50%
in 1996 to 20% in 2001. Along with this decrease in methi-
cillin resistance among blood isolates, the reduction of
methicillin resistance, previously reported by our group,
among all nosocomial S. aureus isolates15 continued: methi-
cillin resistance decreased from 53% to 21% (P < .0001). 
There are two main limitations of our study. First, it
was not controlled. Second, the 1996 data were collected
retrospectively unlike the data from 1997 onward, which
were collected prospectively.
Although we cannot exclude that the decrease in
MRSA BSIs was just due to chance, we are relatively con-
fident about the efficacy of the program for several rea-
sons: (1) the incidence rate of methicillin resistance
among nosocomial isolates of S. aureus in Italy,39 other
European countries, and the United States has progres-
sively increased during the past few years, opposite of
what we observed; (2) the incidence rate of MRSA BSI
decreased after the introduction of the intervention; and
(3) the reduction in MRSA BSI was associated with a sim-
ilar decline in methicillin resistance among S. aureus iso-
lates, probably due to a reduction in the MRSA-colonized
patient reservoir. 
TABLE 1 
INCIDENCE RATE OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS BACTEREMIA PER DEPARTMENT PER 1,000 ADMISSIONS* 
January July 1997– January 2000–
1996– December December Decrease RR Decrease RR
June 1997 1999 2001 Pre vs A Pre to A Pre vs B Pre to B
Department (Period Pre) (Period A) (Period B) (P) (CI95) (P) (CI95)
Overall 0.64 0.42 0.30 34% 0.66 53% 0.46
(.13) (0.39–1.13) (.02) (0.25–0.87)
ICU 6.07 2.66 0.66 56% 0.44 89% 0.11
(.26) (0.11–1.76) (.03) (0.01–0.98)
Medical wards 0.59 0.43 0.36 27% 0.73 39% 0.61
(.38) (0.36–1.49) (.32) (0.27–1.37)
Surgical wards 0.51 0.27 0.21 47% 0.53 59% 0.41
(.31) (0.2–1.43) (.21) (0.13–1.35)
RR = relative risk; CI95 = 95% confidence interval; ICU = intensive care unit.
*Period Pre corresponds to the preintervention phase, period A represents the first period after the introduction of the control program, and period B represents the last 2 years of the study period,
when the program was well known throughout the hospital. Comparisons between period Pre and periods A and B are reported as both reduction in percentage, with P value in parentheses, and RR.
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When we compared our data with those from
Luzzaro et al.,7 which were obtained from 16 hospitals in
the same region and in the same period (1999 to 2000),
the methicillin resistance that we achieved was statistical-
ly significantly greater: 17% in Cremona versus 34% in the
other Lombardy hospitals (RR, 0.49; CI95, 0.30 to 0.81; P <
.0001). Notably, the incidence reported by Luzzaro et al.
was similar to, although slightly higher than, that seen in
our hospital before the program (46%; RR, 1.34; CI95, 0.98
to 1.82; P = .11). 
As per the data of 1996, which were retrospectively
collected, BSI, per se, cannot be misdiagnosed because
we used the same criteria during the entire period: isola-
tion of MRSA from blood cultures. Furthermore, the
reduction in MRSA BSI between intervention periods A
and B was statistically significant even when only prospec-
tively collected data were used. 
Although a specific pharmacoeconomic analysis
was not performed, we estimated that the cost of the pro-
gram, including active surveillance cultures, patient isola-
tion, and treatment of patients, was approximately 25,000
to 30,000 euros per year. This is similar to the cost of 1
to 3 patients with MRSA BSI, based on previous esti-
mates.40-42 We estimate that the amount saved just in
MRSA BSIs may be approximately 100,000 euros per year.
The reduction in MRSA BSIs we obtained definitely paid
for the entire MRSA intervention control program and
probably the entire infection control program for our hos-
pital. 
Our study confirms the statement of the Society for
Healthcare Epidemiology of America33 guidelines for the
control of MRSA and vancomycin-resistant Enterococcus that
the search and isolate strategy represents the main way to
control nosocomial MRSA transmission. This strategy is
effective even in settings with endemic MRSA and high rates
of methicillin resistance among S. aureus isolates. 
To obtain eradication of MRSA, if feasible, we think
that an aggressive approach is needed. Every hospital
should seek to employ this strategy based on national and
international guidelines, specific patient populations, local
medical knowledge and relationships, and financial
resources.
Because a significant reduction was seen in CVC-
associated MRSA BSIs and in MRSA BSIs among ICU
patients, a program of MRSA control should be mandato-
ry in every hospital with a high rate of methicillin resis-
tance or a high incidence rate of CVC-associated MRSA
BSIs and in hospitals with MRSA BSIs in their ICU. More
sophisticated, and probably more expensive, interven-
tions may be necessary to eradicate MRSA from hospitals,
although it is not yet known whether this target is feasi-
ble. 
As outlined by Harbarth and Pittet,29 our hospital
directors should give us the chance to further investigate
this issue. Our patients deserve it.
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